Maturitas
Volume 56, Issue 2 , Pages 129-141 , 20 February 2007

The attitude of gynecologists in São Paulo, Brazil 3 years after the Women's Health Initiative study

Received 19 March 2006 ,Revised 26 June 2006 ,Accepted 27 June 2006.

References 

  1. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease—a statement for healthcare professionals from the American heart association. Circulation. 2001;104:499–503
  2. Bush TS, Barret-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation. 1987;75(Suppl 6):1102–1109
  3. Barret-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the. JAMA. 1989;262:2095–2100
  4. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641–646
  5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49–57
  7. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal, women. Principal results from the Women's Health Initiative randomized controlled, trial. JAMA. 2002;288:321–333
  8. Alving B. NIH asks participants in Women's Health Initiative estrogen-alone study to stop study pills, begin follow-up phase. South Med J. 2004;97:425–426
  9. Heitmann C, Greiser E, Doren M. The impact of the Women's Health Initiative randomized controlled trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause. 2005;12:363–365
  10. Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52:11–17
  11. IMS Health. Information Management and Client Services. Research Latin America. Available at: http://www.imshealth.com/ims/portal/front/indexC/0,2773,6266_43950650_0,00.html. Accessed January 18, 2006.
  12. Blumel JE, Castelo-Branco C, Chedraui PA, et al. Patients’ and clinicians’ attitudes after the Women's Health Initiative. Menopause. 2004;11:57–61
  13. Neyro M, Cancelo MJ, Quereda F, Palacios F. Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain. Climateric. 2005;8:36–48
  14. Nassar AH, Essamad HM, Awwad JT, Khoury NG, Usta IM. Gynecologists’ attitudes towards hormone therapy in the post “Women's Health Initiative” study era. Maturitas. 2005;52:18–25
  15. North American Menopause Society . Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause. 2004;11(6):589–600
  16. International Menopause Society . Guidelines for hormone treatment of women in the menopausal transition and beyond position statement by the Executive Committee of the International Menopause Society. Climacteric. 2004;7:333–337
  17. IBOPE Group. Available at: http://www.ibope.com.br/. Accessed January 25, 2006.
  18. Machado RB, Fernandes CE, Maia E, Melo NR, Baracat EC. Hormone therapy following the Women's Health Initiative (WHI) study: perception of gynecologists in Brazil. Minerva Ginecol. 2005;57:563–568
  19. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21
  20. Beral V Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427
  21. IBGE Instituto Brasileiro de Geografia e Estatística. Available at: http://www.ibge.gov.br/cidadesat/topwindow.htm?1. Accessed January 25, 2006.
  22. Filho AS, Soares Junior JM, Arkader J, Maciel GA, Baracat EC. Attitudes and practices about postmenopausal hormone therapy among female gynecologists in Brazil. Maturitas. 2005;51:146–153
  23. Burger H. Hormone replacement therapy in the post-Women's Health Initiative era. Report a Meeting held in Funchal, Madeira, February 24–25, 2003. Climacteric 2003;6 Suppl 1:11–36.
  24. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril. 2005;84:1589–1601
  25. Speroff L. Alternative therapies for postmenopausal women. Int J Fertil Women Med. 2005;50:101–114
  26. Haimov-Kochman R, Hochner-Celnikier D, Haimov-Kochman R, Hochner-Celnikier D. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us?. Acta Obstet Gynecol Scand. 2005;84:972–979
  27. Sondergaard KM, Hindsberger C, Toft U, Adser L, Damsgaard JJ, Hvas AC. Menopause, hormone therapy and alternative medicine: a cross-sectional study in Roskilde County in 1998. Ugeskr Laeger. 2005;167:3185–3189
  28. Dobson R. Popular herbal remedy for hot flushes is no better than placebo. Br Med J. 2005;331(7522):924
  29. Speroff L. WHI trial: it's time to be critical!. Am J Obstet Gynecol. 2003;189:621–626
  30. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35–44
  31. Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod. 2003;18:1737–1746
  32. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:529–539
  33. Doren M. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis. Osteoporos. 1999;9(Suppl 2):S53–S61
  34. IBOPE Group. Available at: http://www.ibope.com.br/. Accessed January 25, 2006.
  35. McIntosh J, Blalock SJ. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm. 2005;62:69–74
  36. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey. J Womens Health (Larchmt). 2004;13:975–985

☆ The financial support was provided by São Paulo State Foundation for the Support of Research (FAPESP), grant 05/04/16026-0.

PII: S0378-5122(06)00244-1

doi: 10.1016/j.maturitas.2006.06.022

Maturitas
Volume 56, Issue 2 , Pages 129-141 , 20 February 2007

Article Tools